Drug reference
Mycophenolate
Immunosuppressant
Also known as Mycophenolate mofetil
Immunosuppressant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Mycophenolate mofetil is metabolized to mycophenolic acid, which is a more selective purine synthesis inhibitor than azathioprine. This action suppresses immune cell proliferation and function.
Indications
Prophylaxis of acute rejection in renal transplantation (in combination with a corticosteroid and ciclosporin)
Dosing
- Adult
- Oral: 1 g twice daily, to be started within 72 hours of transplantation. Intravenous infusion: 1 g twice daily for maximum 14 days, then transfer to oral therapy (to be started within 72 hours of transplantation).
Pharmacokinetics
Bioavailability
MM: ∼0%; MPA: 94%
Protein binding
MPA: 97.5%
Metabolism
Metabolized to mycophenolic acid
Excretion
MPA: <1%
Side effects
Common
Opportunistic infectionsLeucopenia
Serious
- Tissue-invasive cytomegalovirus infection
Pregnancy & lactation
Lactation
Manufacturer advises avoid—no information available.
Drug interactions
3 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Coronary angiography with renal dysfunction
CSI · Cardiology · 2020
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Acute kidney injury
KDIGO · Nephrology · 2012
Infective endocarditis prevention
NICE · Cardiology / Dentistry · 2008
Infective endocarditis prevention
AHA · Cardiology / Dentistry · 2007
Other Immunosuppressant drugs
Ask House about Mycophenolate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e, Katzung, BNF, Nelson·Updated: 2026-05-10